HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era

HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era

Show other versions (1)

Bibliographic Details
Main Authors:	Montoto, S, Shaw, K, Okosun, J, Gandhi, S, Fields, P, Wilson, A, Shanyinde, M, Cwynarski, K, Marcus, R, de Vos, J, Young, A, Tenant-Flowers, M, Orkin, C, Johnson, M, Chilton, D, Gribben, J, Bower, M
Format:	Conference item
Published:	2011

Similar Items

HIV Status does not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era
by: Orkin, C, et al.
Published: (2012)

HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
by: Montoto, S, et al.
Published: (2012)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
by: Adam F. Binder, et al.
Published: (2017-10-01)

Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report
by: Subbiah Vivek, et al.
Published: (2007-11-01)

S202: CHILDBEARING AMONG CLASSICAL HODGKIN LYMPHOMA SURVIVORS TREATED WITH BEACOPP AND ABVD IN SWEDEN, DENMARK, AND NORWAY
by: J. P. Entrop, et al.
Published: (2022-06-01)

A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma
by: Ryo Yonezawa, et al.
Published: (2023-01-01)

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
by: Schwenkglenks Matthias, et al.
Published: (2010-08-01)

The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
by: Roberto Tamma, et al.
Published: (2023-05-01)

Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort studyResearch in context
by: Marriam Mponda, et al.
Published: (2024-03-01)

Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma
by: Min Hu, et al.
Published: (2023-08-01)

T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
by: Joshua P. Entrop, et al.
Published: (2022-10-01)

PB2260: FIVE-YEAR SINGLE-CENTER EXPERIENCE IN THE TREATMENT OF ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA WITH ABVD
by: Vojin Vukovic, et al.
Published: (2023-08-01)

Clinical profile and outcome of classical Hodgkin lymphoma treated with ABVD protocol at Homi Bhabha Cancer Hospital Varanasi
by: NIKITA SINGH, et al.
Published: (2022-01-01)

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
by: Heidi Mocikova, et al.
Published: (2022-10-01)

Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling
by: Bent Honoré, et al.
Published: (2022-01-01)

Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome.
by: Greaves, P, et al.
Published: (2013)

Partial omission of bleomycin for early‐stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?
by: Jillian R. Gunther, et al.
Published: (2020-07-01)

P033 (0007) SINGLE CENTER ANALYSIS OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA: FOCUS ON R-ABVD AND INTERIM PET
Published: (2018-10-01)

Survival rates of adult patients with Hodgkin lymphoma who underwent ABVD versus escalated BEACOPP in a resource‐limited country: An observational study
by: Tawatchai Suwanban, et al.
Published: (2023-08-01)

P1081: PET-ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH-05 TRIAL
by: A. Pavlovsky, et al.
Published: (2022-06-01)

Prognostic Impact of Serum β<sub>2</sub>-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients
by: Theodoros P. Vassilakopoulos, et al.
Published: (2024-01-01)

P030 (0143) ONCE-A-CYCLE VS. DAILY G-CSF IN EARLY-UNFAVORABLE STAGES OF HODGKIN LYMPHOMA TREATED WITH BEACOPP ESCALATED FOLLOWED BY ABVD
Published: (2018-10-01)

P067: A pilot of lung cancer screening for survivors of Hodgkin lymphoma
by: Rachel Broadbent, et al.
Published: (2022-10-01)

P1082: SAFETY AND EFFICACY ANALYSIS IN OLDER PATIENTS TREATED WITHIN THE GATLA LH-05 PROTOCOL: PET-ADAPTED THERAPY AFTER 3 CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA
by: N. L. Fiad, et al.
Published: (2022-06-01)

P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.
by: Michael Dickinson, et al.
Published: (2023-08-01)

Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD
by: Antonio Santisteban-Espejo, et al.
Published: (2022-10-01)

Effects of ABVD chemotherapy on ovarian function: epidemiology, hormonal dosages and ultrasound morphologic analyses in 270 patients with Hodgkin’s disease
by: Mariavita Ciccarone, et al.
Published: (2023-04-01)

Macrophages in Hodgkin's lymphoma.
by: Pazianas, M
Published: (2010)

Interim results of a UK NCRI randomised trial comparing involved field radiotherapy with no further treatment after 3 cycles ABVD and a negative PET scan in clinical stages IA/IIA Hodgkin lymphoma
by: Radford, J, et al.
Published: (2007)

Macrophages in Hodgkin's lymphoma [2]
by: Pazianas, M
Published: (2010)

The Treatment of Non-Hodgkin's Lymphomas
by: David J. Straus
Published: (2023-08-01)

Genomic Landscape of Hodgkin Lymphoma
by: Magdalena M. Brune, et al.
Published: (2021-02-01)

ORBITAL NON-HODGKIN’S LYMPHOMAS
by: S. V. Saakyan, et al.
Published: (2015-04-01)

EXPERIENCE IN THE TREATMENT OF REFRACTORY HODGKIN’S LYMPHOMA
by: A. M. Chervontseva, et al.
Published: (2021-03-01)

P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma
by: John Radford, et al.
Published: (2022-10-01)

A rare case of paediatric non-Hodgkin's lymphoma
by: D Bhargavi, et al.
Published: (2019-01-01)

Novel Approaches in Molecular Characterization of Classical Hodgkin Lymphoma
by: Diede A. G. van Bladel, et al.
Published: (2022-06-01)

P1085: EVALUATION OF GONADAL FUNCTION IN YOUNG WOMEN DIAGNOSED WITH HODGKIN AND NON-HODGKIN LYMPHOMA
by: A. N. Georgopoulou, et al.
Published: (2022-06-01)

S261: SAFETY AND PRELIMINARY EFFICACY FINDINGS OF AUTO4, A TRBC1-TARGETTING CAR, IN RELAPSED/REFRACTORY TRBC1 POSITIVE SELECTED T CELL NON-HODGKIN LYMPHOMA
by: K. Cwynarski, et al.
Published: (2022-06-01)

Primary Hodgkin’s Lymphoma of the Parotid Gland: A Case Report
by: B. Khademi, et al.
Published: (2007-02-01)